Rapport Therapeutics Azioni (NASDAQ: RAPP)

Ultime notizie per Rapport Therapeutics (NASDAQ:RAPP) Azioni

Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Rapport Therapeutics, Inc. - Common Stock

Rapport Therapeutics Inc

<a href="https://www.reuters.com/business/us-court-extends-pause-nippon-steel-case-seeks-updates-by-june-20-2025-06-13/">https://www.reuters.com/business/us-court-extends-pause-nippon-steel-case-seeks-updates-by-june-20-2025-06-13/</a>

News

General

'US Court extends pause in Nippon Steel case, seeks updates by June 20'- Reuters

Somnigroup International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) has outperformed the market over the past 20 years by 4.18% on an annualized basis producing an average annual return of 12.46%. Currently, Somnigroup International has a market capitalization of $13.25 billion. 
Buying $100 In SGI: If an investor had bought $100 of SGI stock 20 years ago, it would be worth $1,041.64 today based on a price of $63.54 for SGI at the time of writing.
<h3>Somnigroup International's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749847513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Somnigroup International Stock In The Last 20 Years

Offerings

MGRX

Mangoceuticals Files For Mixed Shelf Of Up To $150M

<a href="https://www.axios.com/2025/06/13/david-sacks-xai-meta-ai">https://www.axios.com/2025/06/13/david-sacks-xai-meta-ai</a>

'Key Trump adviser David Sacks selling stakes in xAI, Meta and other AI companies'- Axios

InMed Pharmaceuticals Amends Standby Equity Purchase Agreement With Yorkville; May, From Time To Time, Suspend, Use Of Registration Statement Of Shares Under Sepa With Yorkville

<a href="https://www.bloomberg.com/news/articles/2025-06-13/trump-urged-ergen-carr-to-cut-a-deal-on-echostar-spectrum?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-13/trump-urged-ergen-carr-to-cut-a-deal-on-echostar-spectrum?embedded-checkout=true</a>

SATS

'Trump Urged Ergen, Carr to Cut a Deal on EchoStar Spectrum'- Bloomberg

For all the talk of million-dollar retirements, hitting that seven-figure milestone is a lot rarer than most people assume. In fact, most people won't even come close.
According to the <a href="https://www.federalreserve.gov/econres/notes/feds-notes/greater-wealth-greater-uncertainty-changes-in-racial-inequality-in-the-survey-of-consumer-finances-20231018.html">Federal Reserve's latest Survey of Consumer Finances</a>, just 4.7% of households with retirement accounts have $1 million or more stashed away. And if you're talking about $2 million? That number drops to 1.8%. By the time you hit $3 million, we're in unicorn territory—only <a href="https://www.benzinga.com/personal-finance/24/05/38793057/can-you-guess-how-many-retire-with-a-5-million-nest-egg">0.8% of retirement savers</a> have that much.&nbsp;
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">invest with $1,000 at just $0.30/share.</a></li>
</ul>
So how <a href="https://www.benzinga.com/personal-finance/24/09/41075540/is-your-401-k-balance-above-average-find-out-if-youre-beating-most-savers">much do most people actually have</a>? Among households led by someone between 65 and 74, the average retirement savings is around $609,230. Sounds decent, until you realize the median is only $200,000, meaning half of households have even less than that. For those over 75, the numbers drop further: $462,410 on average, and a median of just $130,000.
The gap between average and median is a flashing red light. A few super-savers are skewing the curve, while the majority fall short—sometimes dangerously short—of what financial advisors recommend. And this isn't about luxury retirements with yachts and infinity pools. This is about affording groceries, property taxes, and health care when you're no longer working.
Part of the issue is access. Nearly half of all households don't even have a retirement account, according to the Federal Reserve. Whether due to low wages, job instability, or a lack of financial education, many people simply never get started—or start too late.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
And even if they do save, how much income does that actually generate?
On average, retired households bring in just under $28,000 per year, according to data from the <a href="https://www.census.gov/programs-surveys/acs.html">American Community Survey</a>. But that figure shifts depending on where you live. In Alaska, retirees average over $36,000 annually, while in Indiana, it's closer to $20,600. Some states, like California and Florida, fall somewhere in between. And the highest retirement income in the country? That belongs to Washington, D.C., with averages topping $43,000.
Of course, averages only tell part of the story. Incomes are often pieced together from a mix of sources. The vast majority of retirees—<a href="https://www.federalreserve.gov/publications/2023-economic-well-being-of-us-households-in-2022-retirement-investments.htm">over 90%—receive Social Security</a>, and for two-thirds, it makes up more than half of their total income. For about one in four, it's their only income. Pensions, if you're lucky enough to have one, come next. Investment income, rental property, and part-time work make up the rest—but not everyone has access to those streams.
So, is $1 million the magic number? Not exactly. Some experts, like Suze Orman, have famously warned that even <a href="https://www.benzinga.com/personal-finance/management/25/06/45818495/suze-orman-says-retiring-early-is-the-biggest-financial-mistake-youll-ever-make-you-might-need-10-millionjust-so-youll-be-fine">$5 million to $10 million might not be enough</a> for a truly "safe" retirement, depending on your lifestyle and inflation. But others argue you can retire comfortably on much less—especially if your home is paid off, you live modestly, and you don't have high medical costs.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
The bottom line: there's no single number that guarantees peace of mind. But the data makes one thing clear—if you're aiming for that seven-figure milestone, you're part of a very small club.
If you're not there yet, don't panic. Instead, focus on consistency. Even small contributions add up over time, especially with compound growth and smart investing. Consider <a href="https://www.benzinga.com/money/are-you-rich">speaking with a financial advisor</a> who can help you create a plan tailored to your income, goals, and timeline.
Retirement might not come with a trophy, but if you can sleep at night knowing your bills are covered and your future is on track—well, that might just be worth more than the million.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2">grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Can You Guess How Many People Retire With $1 Million Saved? Hint: Way Fewer Than You Think

Management

VRAX

Virax Biolabs Group CFO Jason Davis To Resign Effective As Of June 13, 2025

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 17.21% on an annualized basis producing an average annual return of 25.49%. Currently, Intuitive Surgical has a market capitalization of $183.57 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 20 years ago, it would be worth $91,843.40 today based on a price of $512.18 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749846617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

Here's How Much You Would Have Made Owning Intuitive Surgical Stock In The Last 20 Years

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed up 40.45% at $11.91</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 33.78% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 12.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 11.11% at $0.001</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 10.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 9.26% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 8.96% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 7.94% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 5.56% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 5.17% at $0.55</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 3.62% at $0.04</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 50.00% at $0.0004</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 34.74% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 18.52% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 11.83% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/BGRDF">Tony G Co-Investment</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BGRDF#OTC">BGRDF</a>) shares closed down 8.53% at $3.11</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 7.32% at $1.14</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 5.00% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 4.45% at $1.07</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed down 4.44% at $1.29</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 4.26% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 4.17% at $0.79</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 4.06% at $61.15</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.71% at $8.83</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 3.60% at $12.04</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BGRDF

CLSH

CNBX

CNTMF

CRBP

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CVSI

CWBHF

FFNTF

GNLN

GRWG

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

RMHB

SNDL

SOLCF

TGIFF

UGRO

ZDPY

Cannabis Stock Gainers And Losers From June 13, 2025

UUUU

Energy Fuels  Files For Offering Of Up To $300M Common Shares

GDTC

CytoMed Therapeutics Files For Mixed Shelf Of Up To $50M

The legality of hemp is a matter of margins. The Farm Bill legalized hemp-derived cannabinoids in 2018 as long as the plant remained below a threshold of 0.3% Delta-9 THC by dry weight. Cannabis cousin compounds – CBD, THCA, Delta-8 THC, and a slew of minor cannabinoids – were therefore legal provided they met this concentration for Delta-9. The floodgates opened and cannabis products were now available from gas stations to doorstep delivery.
But this rule isn't set in stone. The Farm Bill is meant to be updated every five years and, following two year-long delays, is scheduled for debate and passage this year. This time, senators are fighting back, particularly against psychoactive cannabinoids they view as a loophole in need of closing. 
Early indications suggest lawmakers will push for a total THC standard of 0.3%, potentially curbing access to minor cannabinoids and undoing the scientific, social, and production progress made in this space. Let's take a deeper look at how tenths of a percent will define and ultimately decide the future of legal hemp.
The threshold debate cuts both ways
Last year's postponed draft bill offered the first indication lawmakers wanted to shift from a 0.3% Delta-9 THC standard to a 0.3% total THC standard, encompassing THCA and other THC variants. While this wouldn't likely affect non-THC cannabinoids like CBD, it would target psychoactive cannabinoids.
Ironically, this more restrictive proposal came as other lawmakers argued in the opposite direction. Republican Senator Rand Paul believes the dry weight concentration is too low – and should be tripled – since current rules require testing the flower rather than the final product. This can easily lead to "hot" crops above 0.3%, a real problem with the USDA estimating <a href="https://www.govinfo.gov/content/pkg/FR-2019-10-31/pdf/2019-23749.pdf">about 20% of hemp grown</a> during the crop year exceeds legal THC limits.
Up or down, senators aren't happy with the THC threshold status quo and particularly the newfound legality of psychoactive cannabinoids. This has been a sticking point for conservative lawmakers who feel "duped" that they didn't intend to legalize intoxicating cannabinoids with hemp. As a result, more than 20 states have active bans against cannabinoids like Delta-8, creating a patchwork of production and consumer rules across the country.
A spectrum of cannabinoids
It's worth reiterating that not all cannabinoids are equal. There's an entire world of <a href="https://vitalitycbd.com/what-are-cannabinoids/">more than 120 minor cannabinoids</a> in the hemp plant, with the spectrum ranging from non-psychoactive compounds with solely wellness applications, such as CBD, to psychoactive compounds primarily intended for recreational use, like THCA. And we're only scratching the surface.
The Farm Bill removed red tape and finally let researchers dig into the plant's potential. Early results are promising with CBD proving anecdotal benefits under lab conditions for things like anxiety, inflammation, and sleep. Meanwhile, research into other minor cannabinoids (psychoactive and non-psychoactive) suggests therapeutic applications for conditions such as neuropathic pain, neurodegenerative diseases, skin disorders, and even cancer.
This is important to mention because a total concentration standard could shut the door on some minor cannabinoids and stop this progress in its tracks.&nbsp;
Industry and consumers need clarity
Unfortunately, industry stakeholders will need to wait and see what's next. Congress is getting good at kicking the cannabinoid can down the road, and it seems their legislative agenda is currently focused on the budget. <a href="https://www.agweb.com/news/policy/ag-economy/59-ag-economists-think-congress-wont-pass-new-farm-bill-until-2026">About 60%</a> of agricultural economists believe the Farm Bill – yet again – will go on hold until 2026 due to shifting government priorities.
Regardless of timing, this debate will continue to rage on. And, at the heart of the matter, is how we test products for consumption. I agree that the threshold should be measured against final products rather than raw flower, and producers shouldn't be penalized when concentration factors are often beyond their control. In this regard, there's merit to raising the limit to 1% and only testing the final formulation.
However, it's harder to see the benefit of eliminating psychoactive cannabinoids through a blanket total threshold. From my perspective, as well as that of many in the industry, better production standards and stricter compliance could achieve the same consumer protection goals without further complicating the dry weight framework.
Don't get me wrong – this sector isn't perfect. Some bad actors cut corners on testing and quality, and those of us committed to best practices like organic production, third-party lab verification, and proper labeling welcome rules that raise the bar for consumers. However, a total THC threshold feels like a one-size-fits-all approach that merely seeks to penalize psychoactive cannabinoids. Further, it doesn't address the quality control vacuum left by federal inaction.
Let's hope in the remaining months (or years) of bill debate that industry and lawmakers can come together in good faith to find a solution that works for all sides – one that protects consumers while preserving the promising research and business development we've seen since 2018. Those tenths of a percent may seem insignificant but the stakes couldn't be higher.

Regulations

Opinion

Tenths Of A Percent Will Decide The Future Of Legal Hemp

Rapid7 Appoints Marc Brown As Chairman Of The Board; Corey Thomas To Continue As CEO And Board Member

On June 12, 2025, FibroGen ("FibroGen" or the "Company") entered into a Termination, Asset Transfer and License Agreement (the "Agreement") with HiFiBiO Inc. ("HiFiBiO"). The Agreement terminates the Exclusive License and Option Agreement between the parties, dated June 16, 2021, as amended on February 14, 2024 (the "License Agreement"), and all rights and obligations of FibroGen under the License Agreement shall cease and terminate, subject to certain survival terms.
Under the Agreement, FibroGen has also licensed HiFiBiO the anti-CCR8 and anti-Gal-9 intellectual property developed by FibroGen. In the event HiFiBiO sublicenses Gal-9 (FG-3165) and/or CCR8 (FG-3175) assets, FibroGen is eligible to receive a mid single-digit to low double-digit share of HiFiBiO's license revenues and low double-digit share of HiFiBiO's commercial royalties. In the case HiFiBiO commercializes either asset, FibroGen has the potential to receive single digit royalties based upon worldwide net sales.
﻿

Contracts

FGEN

FibroGen Terminates License Agreement With HiFiBiO, Transfers Anti-CCR8 And Anti-Gal-9 Assets, And Secures Potential Royalties From Future Sublicensing Or Commercialization

Four Corners Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCPT#NYSE">FCPT</a>), a real estate investment trust primarily engaged in the ownership and acquisition of high-quality, net-leased restaurant and retail properties ("FCPT" or the "Company"), is pleased to announce the acquisition of a Tires Plus property for $1.7 million. The property is located in a highly trafficked corridor in Georgia and corporate-operated under a triple net lease with approximately three years of term remaining. The transaction was priced at a 7.4% cap rate on rent as of the closing date and exclusive of transaction costs.
 &nbsp;

FCPT

Four Corners Property Trust Acquires Tires Plus Property For $1.7M

On June 3, 2025, the United States District Court for the District of Connecticut (the "District Court") issued an order granting preliminary approval of the proposed settlement of the consolidated derivative actions captioned In re the Lovesac Company Derivative Action, Case No. 3:24-cv-01260-VAB (D. Conn.), on the terms set out in the Stipulation of Settlement dated May 19, 2025 ("Stipulation of Settlement" and, with its exhibits, the "Settlement Agreement"). On June 6, 2025, the District Court amended the order granting preliminary approval to adjust certain dates in the prior June 3 order.

Legal

LOVE

Federal Court Grants Preliminary Approval Of Lovesac Derivative Lawsuit Settlement On June 3, 2025

Dow Files For Mixed Shelf; Size Not Disclosed

<a href="https://www.bloomberg.com/news/articles/2025-06-13/google-s-plan-to-buy-security-firm-wiz-gets-antitrust-review">https://www.bloomberg.com/news/articles/2025-06-13/google-s-plan-to-buy-security-firm-wiz-gets-antitrust-review</a>

GOOG

GOOGL

'Google's Plan to Buy Security Firm Wiz Gets Antitrust Review'- Bloomberg

Buybacks

FELE

Franklin Electric Completes 1.2M Shares Purchase At $86.78 Each From Patricia Schaefer Settlement Trust

Health Care

Press Releases

CORRECTION -- Rapport Therapeutics Announces New Phase 1 Data, Further Supporting RAP-219's Transformative Potential for CNS Disorders

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Earnings

Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics to Host 2025 Investor and Analyst Day

Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare Conference

Comments

Rapport Therapeutics

Notizie

Ultime notizie per Rapport Therapeutics (NASDAQ:RAPP) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO